ABSTRACT
Objective To analyze the clinical efficacy and toxic reaction of Tegafur,Gimeraciland Oteracil Potassium Capsule combined with Gemcitabine chemotherapy for patients with radical resection for advanced gallbladder carcinoma.Methods The clinical dataof 135 patients with advanced gallbladder cancer who were admitted to the 1 st Affiliated Hospital of Zhengzhou University and supported after the gastrectomy by the pathology from June 2007 to June 2012 were retrospectively analyzed.All patients were divided into three groups by different therapeutic regimens,operation groups (Radical resection or Extended radical resection of gallbladder carcinoma) with 47 cases,chemotherapy A group (Tegafur,Gimeracil and Oteracil Potassium Capsule combined with Gemcitabine chemotherapy after Radical resection or Extended radical resection of gallbladder carcinoma) with 52 cases,and chemotherapy B group (5-Fluorouracil combined with Oxaliplatin chemotherapy after Radical resection or Extended radical resection of gallbladder carcinoma) with 36 cases.We collected the dates of all patients with the median survival time and the 1,3 and 5-year survival rate after operation,and counted the rate of major toxic reaction after chemotherapy.Results There were no significant differences in the general date of three groups (sex,age,tumor size,CA19-9,CA125,TNM stages,with or without cholecystolithiasis,operation methods,operation complication),The chemotherapy A group and chemotherapy B group had no differenceswiththe median survival time and 1,3 and 5-year survival rate after operation.There were significant differences in the median survival time and 3,5-year survival rate after operation between the operation group and chemotherapy A group (or between the operation group and chemotherapy B group).There were significant differences in the rate of whole toxic reaction and the rate of toxic reaction beyond Ⅲ degree between chemotherapy A group and chemotherapy B group.Conclusions The treatment of Tegafur,Gimeracil and Oteracil Potassium Capsule combined with Gemcitabine chemotherapy for patients with radical resection of advanced gallbladder carcinoma has a lower rate of whole toxic reaction and rate of toxic reaction beyond Ⅲ degree than 5-Fluorouracil combined with Oxaliplatin chemotherapy,and for patients with advanced gallbladder carcinoma,the frontal treatment can obviously prolong the median survival time and effectively improve the 3 and 5-year survival rate after operation.
ABSTRACT
Objective:To analyze the efficacy and safety of targeted drug apatinib combined with tegafur, gimeracil and oteracil capsules (TS-1) in the second-line treatment of advanced gastric mucinous adenocarcinoma. Methods: Totally 48 patients with ad-vanced gastric mucinous adenocarcinoma treated with the second-line regimen were randomly divided into the control group and the treatment group with 24 ones in each. The control group received the chemotherapy of TS-1, and the treatment group received apatinib additionally. The adverse reactions and objective effects were observed. Results:The objective response rate (ORR) was 54. 1% and 33. 3% in the treatment and the control group, respectively. The disease control rate (DCR) was 83. 3% and 54. 2% in the treatment and the control group, respectively. There were significant differences on ORR and DCR in both groups(P<0. 05), while no statisti-cal difference was shown in the adverse reactions (P>0. 05) between the two groups. Conclusion:Apatinib combined with TS-1 ex-hibits evident short-term therapeutic effect on advanced gastric mucinous adenocarcinoma, and the adverse reactions can be tolerated.
ABSTRACT
Objective To observe effect and toxicity reaction using the treatment of Docetaxel combined with Gimeracil and Oteracil porassium capsules or capecitabine on elderly patients with advanced gastric cancer.Methods Sventy-eight cases elderly patients with advanced gastric cancer were divided into the combination group (n =40) and the monotherapy group (n =38) randomly by the random number table from February 2010 to December 2012.The patients on the monotherapy group were treated with capecitabine or oral Gimeracil and Oteracil porassium capsules,while the patients on the combination group were treated with Docetaxel in combination of capecitabine or Gimeracil and Oteracil porassium capsules.All therapy were repeated each 3 weeks,and 2 cycles chemotherapy were done at least;meanwhile effect and toxicity reaction were evaluated.At last,time to progress(TTP),median survival time(MST),1-year survival rate and 2-year survival rate were evaluated after completion of follow-up.Results On one other,response rate of the combination group and the monotherapy group were 95％ (38/40) and 79.0％ (30/38),and patients were 38 and 30,respectively;and response rate of the combination group was higher than the monotherapy group(x2 =4.4928;P＜0.05).TTP were 7.9 and 7.6 months on the combination group and the monotherapy group,and the MST were 13.1 months and 12.6 months respectively.The 1-year survival rate were 32.5％,28.95％,and 2-year survival 15.0％,5.27％,similarly,there was no remarkable significance on survival rate(x2=0.12,2.01,P＞0.05).On the other hand,the combination group exhibited more remarkable significance of toxicity reaction than the monotherapy group(P＜0.05),such as hepatotoxicity,baldness,hepatic injury.Conclusion Effect of the combination group was superior to the monotherapy group on elderly patients with advanced gastric cancer.However,there is no longer survival time and more toxicity reaction on the combination group.
ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of tegafur,gimeracil and oteracil potassium combined with oxaliplatin assisting with radiofrequency ablation(RFA)in the treatment of liver metastases after radical operation of rectal cancer. METHODS:A total of 130 patients with liver metastases after radical operation of rectal cancer were randomly divided into control group and observation group,with 65 cases in each group. After RFA one week,control group was given Oxaliplatin injection 130 mg/m2 intravenously,d1,more than 3 h. Observation group was additionally given Tegafur capsule,for consecutive 14 d,drug with-drawal of 7 d,as a treatment course. A treatment course lasted for 3 weeks,and both groups received 2 courses of treatment. Short-term efficacies of 2 groups were observed as well as complete ablation rate,local recurrence rate,survival rate and the occur-rence of toxic reaction. RESULTS:The total remission rate,disease control rate,complete ablation rate,1-year,2-year and 3-year survival rates of observation group were significantly higher than those of control group,and local recurrence rate was significantly lower than control group,with statistical significance(P0.05). CONCLUSIONS:Tegafur,gimeracil and oteracil potas siucn combined with oxaliplatin assisting with RFA shows significant therapeutic efficacy for liver metastase after radical operation of rectal cancer,and can significantly de-lay disease progression,reduce local recurrence rate and prolong survival time,and does not increase the occurrence of toxic reac-tion.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of capecitabine and tegafur gimeracil and oteracil potassium synchronous radiotherapy in the treatment of recurrence after radical resection of colon cancer. METHODS:A total of 150 patients with recurrent after radical resection of colon cancer in our hospital during Jan. 2012-Dec. 2012 were divided into group A and B ac-cording to random number table,with 75 cases in each group. Both groups received three-dimensional conformal radiotherapy. Group A was additionally given capecitabine 2.5 g. Group B was additionally given tegafur gimeracil and oteracil potassium,40 mg,bid for body surface area <1.25 m2,50 mg,bid for body surface area ranged 1.25-1.50 m2 and60mg,bid for body surface ar-ea<1.50 m2. Clinical efficacies of 2 groups were compared;1-year,2-year,3-year survival andⅢ-Ⅳdegree toxic effect were fol-lowed up. RESULTS:The total response rate of group B was 86.67％,which was significantly higher than 66.67％ of group A, with statistical significance(P<0.05). 1-year,2-year,3-year survival rates of group B were 93.335,72.00％,58.67％,which was significantly higher than 74.67％,53.33％,41.33％,with statistical significance(P<0.05). The median disease progression time of group A was 8.0 months,which was significantly shorter than 9.5 months of group B,with statistical significance (P<0.05). There was no statistical significance in Ⅲ-Ⅳ degree toxic effect between 2 groups (P<0.05). CONCLUSIONS:Compared with capecitabine,tegafur gimeracil and oteracil potassium combined with three-dimensional conformal radiotherapy show significant therapeutic efficacy for recurrence after radical resection of colon cancer,can control disease progression,prolong the survival time and don't increase the risk of toxic effects.
ABSTRACT
OBJECTIVE:To compare therapeutic efficacy and safety of lobaplatin or cisplatin combined with tegafur,gimeracil and oteracil potassium in the treatment of advanced metastatic breast cancer.METHODS:A total of 160 patients with advanced metastatic breast cancer were randomly divided into observation group and control group,with 80 cases in each group.Control group was given Cisplatin injection 30 mg/m2 intravenously,every 3 weeks Tegafur,Gimeracil and Oteracil Potassium capsules 50 mg orally after meal,twice a day,for consecutive 14 days.Observation group was given Lobaplatin for injection 30 mg/m2 intravenously,every 3 weeks+Tegafur,Gimeracil and Oteracil Potassium capsules (same usage and dosage as control group),every 3 weeks.A treatment course lasted for 3 weeks,and both groups received 2 courses.Short-term efficacies (ORR、DCR),chemotherapy effects of lymph node,lung,bone and liver,ADR and long-term efficacy were compared between 2 groups.RESULTS:After treatment,ORR(67.50％ vs.46.25％),DCR(85.00％ vs.66.25％),ORR of lymph node metastasis (71.43％ vs.47.83％),ORR of lung metastasis (60.71％ vs.40.00％),DCR of lung metastasis (78.57％ vs.56.00％),ORR of bone metastasis (28.57％ vs.16.67％),1-year survival rates (75.00％ vs.52.50％) and 2-years survival rates (42.50％ vs.17.50％) of observation group were significantly higher than control group;the incidence of chemotherapy ADR in observation group was significantly lower than control group (43.75％ vs.70.00％),with statistical significance (P＜0.05).There was no statistical significance in lymph node metastasis DCR,bone tissue metastasis DCR,liver metastasis ORR and DCR,or half year sarvival rate between 2 groups (P＞0.05).CONCLUSIONS:Compared to cisplatin combined with tegafur,gimeracil and oteracil potassium,lobaplatin combined with tegafur,gimeracil and oteracil potassium show better short-term therapeutic efficacy,therapeutic efficacy of lymph node metastasis,bone metastasis and lung metastasis,more than 1-year long-term therapeutic efficacy and safety in the treatment of advanced metastatic breast cancer.
ABSTRACT
Objective:To analyze the efficacy and safety of targeted drug apatinib combined with tegafur, gimeracil and oteracil capsules (TS-1) in the second-line treatment of advanced gastric mucinous adenocarcinoma. Methods: Totally 48 patients with ad-vanced gastric mucinous adenocarcinoma treated with the second-line regimen were randomly divided into the control group and the treatment group with 24 ones in each. The control group received the chemotherapy of TS-1, and the treatment group received apatinib additionally. The adverse reactions and objective effects were observed. Results:The objective response rate (ORR) was 54. 1% and 33. 3% in the treatment and the control group, respectively. The disease control rate (DCR) was 83. 3% and 54. 2% in the treatment and the control group, respectively. There were significant differences on ORR and DCR in both groups(P<0. 05), while no statisti-cal difference was shown in the adverse reactions (P>0. 05) between the two groups. Conclusion:Apatinib combined with TS-1 ex-hibits evident short-term therapeutic effect on advanced gastric mucinous adenocarcinoma, and the adverse reactions can be tolerated.
ABSTRACT
Objective To evaluate the efficacy and toxicity of gimeracil and oteracil porassium capsules combined with nedaplatin in the treatment of the patients with distant metastatic nasopharyngeal carcinoma.Methods Fourty cases were randomly divided into the observation group and control group by random digital table.19 cases in the observation group were treated with oteracil potassium capsules combined with nedaplatin.21cases in the observation group were treated with gemcitabine combined with nedaplatin.The response rate,response rate(RR) and progression free survival(PFS),toxicity were evaluated according to response evaluation criteria in solid tumors (RECIST).Results The response rate were 52.6％,52.3％ respectively,the median progression-free survival were 5.5 and 5.2 months,respectively.Grade Ⅲ an Ⅳ platelet supression were 10.5％,38.0％ between the observation group and control group.It was statistically significant between the two group(x2 =4.89,P ＜ 0.05).Conclusion Oteracil porassium capsules combined with nedaplatin is similar with gemcitabine combined with nedaplatin in the distant metastatic nasopharyngeal carcinoma,the adverse reaction was lighter than that of the control group.
ABSTRACT
Objective To evaluate the efficacy and adverse reaction of continuous low-dose oral Tegafur,Gimeracil and Oter-acil Potassium Capsules in combination with small dose of transcatheter arterial chemoembolization(TACE)in the treatment of pri-mary hepatocarcinoma patients.Methods A total of 92 primary hepatocarcinoma patients who were unable or unwilling to surgery. Patients were divided into treatment group and control group,with each consisted of 46 cases.The treatment group was given con-tinuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules in combination with small dose of TACE,and the control group was given small dose TACE.All study subjects were reviewed DSA and CT.tumor angiogenesis and tumor staining,Karnof-sky Performance Scores(KPS),postoperative adverse events and complications was evaluated.PFS and the survival rate of three months,six months,one year and two years was estimated.Results Tumor angiogenesis and staining were significantly lower in treatment group than those of the control group(P 0.05).KPS scores in the two groups had no significant difference before and after treatment(P >0.05 ).PFS,one year and two years survival rate were better in treatment group than in the control group(P <0.05).Conclusion Combined appli-cation of continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE was significantly su-perior to TACE alone in the treatment of primary hepatocarcinoma patients.
ABSTRACT
Objective To compare the effect of gimeracil and oteracil porassium capsules ( S-1 ) combined with docetaxel and capecitabine combined with docetaxel in the treatment of metastatic breast cancer .Methods Ac-cording to the digital table ,88 patients with metastatic breast cancer were randomly divided into the observation group and control group ,44 cases in each group .The observation group received S-1 combined with docetaxel treatment ,the control group received capecitabine combined with docetaxel treatment .The total effective rate ,progression free surviv-al,quality of life and the incidence of adverse reactions were compared between the two groups .Results The total effective rate of the observation group was 75.00%,which was significantly higher than 38.64%of the control group (χ2 =2.199,P<0.05).The progression free survival time in the observation group was (10.53 ±3.21) months, which was significantly longer than (5.72 ±2.10)months in the control group(t=0.667,P<0.05).After 3 months of follow-up,the body,social support,psychological,spiritual and other 4 factor scores of patients in the observation group were better than those in the control group (t=2.885,2.326,3.379,5.503,all P<0.05),the quality of life greatly improved .Conclusion The clinical efficacy of S-1 combined with docetaxel in the treatment of metastatic breast cancer is exact ,adverse reactions can be tolerated ,it can be used as a new clinical scheme of chemotherapy for metastatic breast cancer .
ABSTRACT
Objective To study the curative effect and clinical safety of gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric carcinoma patients.Methods From January 2009 to December 2011,116 cases with advanced gastric carcinoma were randomly chosen and divided into group A,B (58 cases in each group).Group A was given gimeracil and oteracil potassium combined with oxaliplatin,while group B was given oxaliplatin,fluorouracil and calcium folinate.Before and after dosing,the blood routine,liver and kidney function,chest CT scanning and gastroscope inspection were observed,the recent curative effect and adverse reaction of chemotherapy were analyzed.The patients' survival time and disease progression were compared.Results The curative effect of 116 patients could all be evaluated,and the effective rate of group A and group B were 48.3％(28/58) and 29.3％(17/58),while clinical benefit rate were 74.1％(43/58) and 55.2％(32/58),there was significant difference(P ＜ 0.05).The survival rate of two groups at different time points had no significant difference (P ＞0.05).The rate of nauseated and vomiting were 34.5％(20/58),37.9％(22/58) in group A,and 67.2％(39/58),62.1％(36/58) in group B,there was significant difference (P ＜ 0.05).The influence of drugs on blood system,common peripheral neurotoxicity,extremities syndrome and inflammation of the oral mucosa between two groups had no significant difference (P ＞0.05).Conclusions Gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric carcinoma patients has better clinical effect and less complication,which is worthy of further promotion.
ABSTRACT
Objective To test comparative effect of capecitabine and S-1 (Tegafur/gimeracil/oteracil) on advanced colorectal cancer.Methods 106 cases of advanced colorectal cancer in our hospital oncology were collected and randomly divided into 2 groups:capecitabine group (52 cases) and S-1 group (54 cases).The chemotherapy effect and adverse effect of 2 groups were collected.Results After one treatment period,3 cases of complete remission,19 cases of partial remission,15 cases of stable disease,15 cases of disease progression,efficient rate of 42.3％and control rate of 71.2％ were observed in capecitabine group.5 cases of complete remission,21cases of partial remission,19 cases of stable disease,9 cases of disease progression and efficient rate of 48.1％ and control rate of 83.3％ were observed in S-1 group.There were no significant differences in efficient rate,control rate adverse effect rate and survival time between 2 groups(P ＞ 0.05).Conclusion Capecitabine and S-1 are both safe and effective in treatment of advanced colorectal cancer.
ABSTRACT
Objective To investigate the clinical efficacy of S-1 combined with cisplatin in the treatment of old patients with advanced gastric cancer.Methods 85 patients were randomly divided into two groups.Experimental group was treated by S-1 combined with cisplatin,while control group was treated by 5-FU and cisplatin.Short-term efficacy and adverse reactions were evaluated after four cycles.Results All patients had succcssfully accomplished chemotherapy.Compared with the control group ( RR =52.4％,DCR =81.0％ ),RR and DCR in experimental group ( RR =67.4％,DCR =93.0％ ) had statistically significant difference ( P ＜ 0.05 ).The top three of adverse reactions and complications in patients of the two groups were:nausea and vomiting,low WBC,low hemoglobin concentration.Compared with the control group,the toxicity in experimental group had no statistically significant difference ( P ＞0.05).All patients were followed up with a meau of( 15.5 - 2.7 ) months.The 1 year survival rate was 60.5％(26/43) in the experimental group; the 1 year survival rate was 52.4％ (21/42) in the control group.There was no statistically significant difference( P ＞ 0.05 ).Conclusion The S-1 combined with cisplatin had shown better efficacy in the treatment of old patients with advanced gastric carcinoma,and the toxicity was relatively mild and tolerable.
ABSTRACT
Objective: To evaluate the efficacy and toxicity of docetaxel combined with tegafur,gimeracil and oteracil potassium (S-1) capsules in the treatment of patients with advancedadenocarcinoma of esophagogastric junction (AEG). Methods: Fifty-eight patients with advanced AEGwere recruited in this study between January 2009 and January 2011. All patients were treated withchemotherapy of docetaxel (35 mg·m-2·d-1 on d 1 and d 8; intravenous injection) combined with S-1capsule (70 mg/m2 daily for 14 days). The chemotherapy cycle was repeated every 21 days. The short-termresponse and the toxicity were evaluated every two cycles and one cycle, respectively. The follow-upexaminations were performed in all patients, and the survival was calculated. Results: Of the 58 patients,there were 5 patients (8.6%) with complete response, 21 patients (36.2%) with partial response, 18patients (31.0%) with stable disease, and 14 patients (24.1%) with progressive disease. The total responserate was 44.8% (26/58). The median time to progression was 8.0 months, and the median survival timewas 10.5 months. The major toxicities included leucopenia, stomatitis, hand-foot syndrome and adversereactions of gastrointestinal tract. The rate of grade ¢ó-¢ô leucopenia was 25.9% (15/58). Conclusion: Docetaxel combined with S-1 capsule is effective and tolerable in the treatment of patients with advanced AEG. Copyright© 2011 by TUMOR.